Literature DB >> 2292540

Treatment of acute exacerbations of chronic obstructive airways disease--a comparison of amoxycillin and ciprofloxacin.

G S Basran1, J Joseph, A M Abbas, C Hughes, G S Tillotson.   

Abstract

Ciprofloxacin and amoxycillin were compared in the treatment of acute exacerbations of chronic obstructive airways disease. One hundred and forty patients were evaluable for overall outcome: 60 patients' sputum specimens yielded positive bacteriological cultures. The predominant pathogens were Haemophilus influenzae (43.3%) and Streptococcus pneumoniae (25.0%). Both regimens were safe and produced few adverse effects. An independent observer judged ciprofloxacin to produce a 91.8% success rate (complete success 21.9%; partial success 69.9%) whilst a 73.1% rate (complete success 10.4%; partial success 62.7%) was seen with amoxycillin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2292540     DOI: 10.1093/jac/26.suppl_f.19

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Antibiotic resistance in common acute respiratory pathogens.

Authors:  P Venkatesan; J A Innes
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

2.  Antibiotics in chronic obstructive pulmonary disease.

Authors:  H Hosker; N J Cooke; P Hawkey
Journal:  BMJ       Date:  1994-04-02

3.  Fluoroquinolones in upper respiratory tract infections.

Authors:  M Spiteri
Journal:  BMJ       Date:  1994-03-05

4.  Fluoroquinolones in chronic obstructive pulmonary disease.

Authors:  A Colville; M Knowles; D Large; J George; P Mustchin
Journal:  BMJ       Date:  1994-05-28

5.  Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice.

Authors:  A P Sachs; G H Koëter; K H Groenier; D van der Waaij; J Schiphuis; B Meyboom-de Jong
Journal:  Thorax       Date:  1995-07       Impact factor: 9.139

6.  Rufloxacin once daily in acute exacerbations of chronic bronchitis.

Authors:  M Dirksen; J Focht; J Boerema
Journal:  Infection       Date:  1991 Jul-Aug       Impact factor: 3.553

Review 7.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

Review 8.  Epidemiology and treatment of chronic bronchitis and its exacerbations.

Authors:  P Ball
Journal:  Chest       Date:  1995-08       Impact factor: 9.410

Review 9.  Airway infection.

Authors:  M Niroumand; R F Grossman
Journal:  Infect Dis Clin North Am       Date:  1998-09       Impact factor: 5.982

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.